Organization
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
9 clinical trials
Clinical trial
A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in Sub-Saharan Africa Living With HIV During a Monitored Analytical Treatment InterruptionStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Two Long-Acting Broadly Neutralizing Antibodies at ART Initiation in Adults Living With HIV-1 in Sub-Saharan Africa: The ACACIA StudyStatus: Not yet recruiting, Estimated PCD: 2029-02-16
Clinical trial
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)Status: Completed, Estimated PCD: 2023-08-21
Clinical trial
A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TBStatus: Not yet recruiting, Estimated PCD: 2029-04-01
Clinical trial
Pharmacokinetic Interactions of Etonogestrel (ENG) Subdermal Implants With Long-Acting (LA) Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) in Participants of Reproductive PotentialStatus: Withdrawn, Estimated PCD: 2024-08-02
Clinical trial
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune ResponsesStatus: Active (not recruiting), Estimated PCD: 2020-12-02
Clinical trial
The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive TuberculosisStatus: Completed, Estimated PCD: 2021-09-22